[go: up one dir, main page]

PE20020754A1 - Complejos de inclusion de ciclodextrina-drospiperona - Google Patents

Complejos de inclusion de ciclodextrina-drospiperona

Info

Publication number
PE20020754A1
PE20020754A1 PE2001001281A PE2001001281A PE20020754A1 PE 20020754 A1 PE20020754 A1 PE 20020754A1 PE 2001001281 A PE2001001281 A PE 2001001281A PE 2001001281 A PE2001001281 A PE 2001001281A PE 20020754 A1 PE20020754 A1 PE 20020754A1
Authority
PE
Peru
Prior art keywords
solution
cyclodextrin
drosperidone
solvent
inclusion complex
Prior art date
Application number
PE2001001281A
Other languages
English (en)
Inventor
Wolfgang Heil
Thomas Backensfeld
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20020754A1 publication Critical patent/PE20020754A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN COMPLEJO DE INCLUSION FORMADO ENTRE O-, ß-, Ô-CICLODEXTRINA Y DE 0,1mg A 10mg DE DROSPERIDONA (6ß,7ß,15ß,16ß-DIMETILEN-3-OXO-17O-PREGN-4-EN-21,17-CARBOLACTONA) EN UNA PROPORCION DE 1:1, 2:1, 3:1, 3:2, 1:2, 2:2, 2:3, 1:3. TAMBIEN SE REFIERE A UN METODO PARA PRODUCIR EL COMPLEJO DE INCLUSION QUE COMPRENDE COMBINAR DROSPERIDONA SOLIDA O EN SOLUCION CON CICLODEXTRINA EN SOLUCION, SIENDO LOS SOLVENTES AGUA, ETANOL, ACETONA, ACETONITRILO, METANOL, PIRIDINA, OPCIONALMENTE CALENTADO; AGITAR LA SOLUCION MIENTRAS SE MANTIENE LA SOLUCION A 25°C, FILTRAR EL PRECIPITADO RESULTANTE; LAVAR EL PRECIPITADO CON UN SOLVENTE ENFRIADO POR DEBAJO DE 25°C, SUSPENDER EL SOLIDO RESULTANTE EN ACETONA, LAVAR EL MATERIAL SUSPENDIDO CON UN SOLVENTE PREFERIBLEMENTE ENFRIADO POR DEBAJO DE 25°C, ELIMINAR TODO EL SOLVENTE DEL MATERIAL RESULTANTE O SUSPENDIDO POR PULVERIZACION O LIOFILIZACION. EL COMPLEJO MEJORA LA SOLUBILIDAD DE LA DROSPERIDONA CON EL COMPLEJO DE INCLUSION Y PUEDE SER UTIL COMO ANTICONCEPTIVO FEMENINO O PARA EL TRATAMIENTO DE SINTOMAS MENOPAUSICOS
PE2001001281A 2000-12-20 2001-12-20 Complejos de inclusion de ciclodextrina-drospiperona PE20020754A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00610134A EP1216712A1 (en) 2000-12-20 2000-12-20 Cyclodextrin-drospirenone inclusion complexes

Publications (1)

Publication Number Publication Date
PE20020754A1 true PE20020754A1 (es) 2002-08-23

Family

ID=8174431

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001281A PE20020754A1 (es) 2000-12-20 2001-12-20 Complejos de inclusion de ciclodextrina-drospiperona

Country Status (6)

Country Link
US (2) US6610670B2 (es)
EP (1) EP1216712A1 (es)
AR (1) AR032204A1 (es)
AT (1) ATE543514T1 (es)
ES (1) ES2380653T3 (es)
PE (1) PE20020754A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
EP1216712A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
US20050222106A1 (en) * 2004-04-01 2005-10-06 Stefan Bracht Drospirenone-containing preparations for transdermal use
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
US8617597B2 (en) * 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
WO2009100871A2 (en) * 2008-02-13 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Drug delivery system with stabilising effect
MX2010008940A (es) * 2008-02-13 2010-10-05 Bayer Schering Pharma Ag Sistemas de administracion de drogas que contienen estradiol.
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
CA2796139A1 (en) 2010-04-15 2011-10-20 Bayer Intellectual Property Gmbh Low-dosed solid oral dosage forms for hrt
KR20180018827A (ko) 2010-04-15 2018-02-21 바이엘 인텔렉쳐 프로퍼티 게엠베하 초저-용량의 ｈｒｔ용 고체 경구 투여 형태
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
HU190356B (en) * 1981-10-27 1986-08-28 Richter Gedeon Vegyeszeti Termekek Gyara Rt,Hu Process for preparing steroid-gamma-cyclodextrin inclusion complexes with high water-solubility
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US5229370A (en) 1988-08-15 1993-07-20 Ammeraal Robert N Water soluble branched beta cyclodextrin steroid complex
DE3916112A1 (de) * 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
US6346518B1 (en) * 1993-03-10 2002-02-12 Janssen Pharmaceutica N.V. Itraconazole and saperconazole stereoisomers
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4426709A1 (de) * 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
JP2920611B2 (ja) 1995-12-11 1999-07-19 株式会社シーエーシー 皮膚炎の治療外用剤
US5888543A (en) * 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
EP1216712A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes

Also Published As

Publication number Publication date
EP1216712A1 (en) 2002-06-26
US20030212043A1 (en) 2003-11-13
US6610670B2 (en) 2003-08-26
ATE543514T1 (de) 2012-02-15
ES2380653T3 (es) 2012-05-17
US20020128229A1 (en) 2002-09-12
AR032204A1 (es) 2003-10-29

Similar Documents

Publication Publication Date Title
PE20020754A1 (es) Complejos de inclusion de ciclodextrina-drospiperona
CY1105299T1 (el) Χρηση των επιλεκτικων αγωνιστων του υποδοχεα 4 (ep4) προσταγλανδινης (pge2) για τη θepαπεια της οξειας και χρονιας νεφρικης ανεπαρκειας
ES2132352T3 (es) Un reactivo para medir leucocitos inmaduros.
ES2180938T3 (es) Donadores de oxido nitrico capaces de reducir la toxicidad de los farmacos.
AR029737A1 (es) Concentrados de anticongelantes a base de amidas y composiciones refrigerantes que los comprenden, para la proteccion del magnesio y aleaciones de magnesio
AR052069A1 (es) Composiciones detergentes liquidas substancialmente no acuosas y su utilizacion
UY26920A1 (es) 7 - oxo piridopirimidinas
CR7059A (es) USO DE AGONISTAS INVERSOS DE GABAa EN COMBINACION CON AGONISTAS PARCIALES DEL RECEPTOR DE NICOTINA, ESTROGENOS, MODULADORES SELECTIVOS DE ESTROGENOS O VITAMINA E PARA EL TRAMIENTO DE TRASTORNOS COGNITIVOS
ES2186197T3 (es) Procedimiento de solubilizacion de principios farmaceuticamente activos en agua y en vehiculos acuosos.
BR112014026133A2 (pt) implante espacador para a substituição temporária de uma prótese de joelho
SE0003616D0 (sv) Farmaceutiskt acceptabel stärkelse
BRPI0413957A (pt) processo para preparar diterpenos solúveis em água, solução aquosa e suas aplicações
CO5680425A2 (es) Formulaciones liofilizadas de cci-779
DE60104853D1 (de) Zusammensetzung enthaltend folsäure und zink für das verbessern der semen qualität
TR200302297T4 (tr) (SS, RS)-S-adenozil-L-metiyoninin farmasötik olarak kabul edilebilir tuzlarının hazırlanması için bir işlem
DE60023720D1 (de) Zusammensetzung für inhalierung enthaltend delta-9-tetrahydrocannabinol in einem semi-wässrigen lösungsmittel
AR046672A1 (es) Prevencion y tratamiento de enfermedaes cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,6(10)-trien-3,16alfa-diol
ZA200704681B (en) Metal complex dye mixtures
EP1411967A4 (en) BLOCKING PEPTIDE FOR THE SECRETION OF INFLAMMATORY CELLS
Kazemi et al. Membrane transport of Cu (II) with a cooperative carrier composed of dibenzodiaza-15-crown-4 and oleic acid
ES2194640T3 (es) Solucion acuosa estable del derivado de la talidomida (em 12), para su administracion parenteral, y su procedimiento de preparacion.
IT1318547B1 (it) Impiego dell'aloe-emodin nel trattamento di patologie neoplastiche diorigine neuroectodermica.
AR047461A1 (es) Formacion, purificacion y uso de n-formilolanzapina
Akhond et al. Specific Uphill Transport of Zinc as Zn (SCN) 42− Ion using Na+‐Dicyclohexyl‐18‐Crown‐6 as Carrier
RU2008129099A (ru) Композиции для лечения волос

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed